Breaking News: Neuronetics and Greenbrook TMS Join Forces in Exciting Merger!

MALVERN, Pa. and TORONTO, Dec. 10, 2024

Neuronetics, Inc. (NASDAQ: STIM) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) have officially joined forces in an exciting merger. This strategic move brings together two leading companies in the field of transcranial magnetic stimulation (TMS) to create a stronger, more innovative organization moving forward.

The Merger Details

The transaction involved Neuronetics acquiring all the issued and outstanding common shares of Greenbrook through a court-approved plan of arrangement under the Business Corporations Act (Ontario). Each Greenbrook Share was exchanged for 0.01021 of a share of Neuronetics common stock, solidifying the merger and creating the Combined Company.

With this merger, Neuronetics and Greenbrook are poised to capitalize on their respective strengths and expertise to drive advancements in TMS technology and treatment options for patients with neurological and psychiatric disorders.

This merger will result in a more comprehensive range of TMS solutions and resources, with the goal of improving patient outcomes and expanding access to innovative treatment options.

How Will This Merger Affect Me?

As an individual seeking treatment for neurological or psychiatric disorders, the merger of Neuronetics and Greenbrook means access to a broader array of cutting-edge TMS therapies and technologies. This merger could potentially lead to more effective treatments and better outcomes for patients like you.

How Will This Merger Affect the World?

On a larger scale, the merger of Neuronetics and Greenbrook has the potential to impact the world by advancing research and development in TMS technology. By combining their resources and expertise, the Combined Company can drive innovation in the field of neuromodulation, potentially leading to new breakthroughs that benefit patients worldwide.

Conclusion

The merger of Neuronetics and Greenbrook represents a significant step forward in the field of transcranial magnetic stimulation. By combining their strengths and resources, the Combined Company is well-positioned to drive innovation, improve patient outcomes, and advance the field of neuromodulation. This exciting merger has the potential to positively impact individuals seeking treatment for neurological and psychiatric disorders, as well as contribute to advancements in TMS technology on a global scale.